Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
MBAI stock price ended at $1.66 on 星期五, after rising 9.21%
On the latest trading day Feb 06, 2026, the stock price of MBAI rose by 9.21%, climbing from $1.54 to $1.66. Throughout the session, the stock experienced a volatility of 11.41%, with prices fluctuating between a daily low of $1.49 and a high of $1.66. Alongside this price increase, trading volume also rose by 50.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 105.5K shares were traded, amounting to a market value of approximately $11.6M.